Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20985069 | 0.93 | MAPK1 (0.53) | LMNASMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL28333071 | 0.89 | LMNA (0.54) | LMNASMN1; SMN2LGALS8L3MBTL1HTT | |
| SCHEMBL7768969 | 0.89 | LGALS8 (0.51) | LGALS8CA1CA2CA9MAPT | |
| SCHEMBL24239904 | 0.88 | LMNA (0.52) | LMNASMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL22855653 | 0.88 | MAPK1 (0.57) | LGALS8MAPK1MEN1KMT2A | |
| SCHEMBL24699869 | 0.88 | MAPK1 (0.57) | LGALS8MAPK1MEN1KMT2A | |
| SCHEMBL17283441 | 0.86 | MAPK1 (0.60) | LGALS8MAPK1MEN1KMT2A | |
| SCHEMBL30980624 | 0.86 | MAPK1 (0.52) | LMNASMN1; SMN2LGALS8MAPK1MEN1 | |
| SCHEMBL2002256 | 0.85 | LGALS8 (0.42) | LMNALGALS8CA1CA2CA9 | |
| SCHEMBL2002254 | 0.85 | LGALS8 (0.42) | LMNALGALS8CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960523-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080033155-A1 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-7288640-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| WO-2006012425-A2 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | DDOST, AGL, GALE | LMNA 4696/4885SMN1; SMN2 4829/4885LGALS8 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.